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Purpose: Natural killer cells (NK cells) play important roles in protecting the patient from the early
development of cancers, and are activated or inhibited by killer cell immunoglobulin-like receptors (KIR),
which bind to HLA class I. In the present study, we investigated the KIR genotype of Korean colorectal
cancer patients.
Methods: DNA samples were extracted from peripheral blood cell samples taken from Korean colorectal
cancer patients and a control group. KIR genes were ampliﬁed using PCR-SSP methods, and HLA-Cw
genes were characterized using PCR methods. The results were analyzed to assess the difference be-
tween colorectal cancer patients and the normal control group.
Results: In the present study, the frequency of KIR2DS5 (33.2% vs. 20.8%, p-value < 0.007) was higher in
the colorectal cancer group, and in the rectal cancer subgroup, the frequencies of KIR3DL1 (93.2%, vs.
98.1%, p-value < 0.05), KIR2DS2 (7.8% vs. 19.5%, p-value < 0.01), and KIR2DS4 (93.2% vs. 98.1%, p-
value < 0.05) were lower signiﬁcantly. The frequencies of HLA-Cw6 (9.1% vs. 15.7%, p-value < 0.05) and
HLA-Cw7 (17.4% vs. 27.7%, p-value < 0.02) were lower in the colorectal cancer group. Of the patients with
HLA-C1 homozygote, the frequency of KIR2DS2 was decreased signiﬁcantly (5.8% vs. 14.5%, p-
value < 0.004).
Conclusions: The frequency of KIR2DS5 is higher in Korean colorectal cancer patients, and in the rectal
cancer subgroup, the frequencies of KIR3DL1, KIR2DS2 and KIR2DS4 are lower. Among the patients with
HLA-C1 homozygote, the frequency of KIR2DS2 is decreased. Therefore, KIR2DS2 in presence of its ligand
(HLA-C1 group) may have a protective effect against colorectal cancer.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Colorectal cancer is the one of themost common incident cancer
worldwide [1]. In Korea, incidence of colorectal cancer has
increased annually. And colorectal cancer has become the second
most common cancer after stomach cancer among men and theul St. Mary's Hospital, College
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f of Surgical Associates Ltd.third most common cancer after cancers of the thyroid and breast
among women in Korea [2].
A wide range of genetic and environmental factors are involved
in the development and progression of colorectal cancer. The im-
mune system of the patient also plays an important role during
early cancer cell elimination and protection against metastasis.
Overcoming the patient's immune system is critical to tumor
growth. Of the various elements of a patient's immune system, the
innate immunity is responsible for the ﬁrst protection against the
cancer cells [3].
Natural killer cells (NK cells), which constitute about 10e15% of
the peripheral lymphocytes, are among the most important of the
innate immune cells, and can destroy cancer cells without previous
sensitization [3,4].
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these, killer cell immunoglobulin-like receptors (KIR, CD158),
which recognize human leukocyte antigen (HLA) class I as their
ligands, can activate or inhibit NK cells plays an important role in
controlling the function of NK cells [5]. KIR types are classiﬁed into
an inhibitory group with a long (L) intracytoplasmic tail and an
activating group with a short (S) intracytoplasmic tail. The genetic
distribution of KIR genes effects the expression of KIR on NK cells,
though ethnic differences in KIR genotypes have been observed [6].
KIR genes are encoded on chromosome 19q13.4. The KIR gene
cluster comprises up to 16 highly homologous and closely linked
genes and pseudogenes [7]. And there are 7 kinds of inhibiting
genes and another 7 kinds of activating genes [8].
The ligands of KIR are HLA class I (A, B, C), and most previous
studies have been focused on the HLA-C alleles. HLA-C alleles can
be divided into the HLA-C1 group that carries an asparagines res-
idue at position 80 and HLA-C2 group that has a lysine residue at
position 80 [9]. It is known that KIR2DL1 and KIR2DS1 bind to HLA-
C2, and KIR2DL3, KIR2DS2, and KIR2DL2 bind to HLA-C1 [10].
Speciﬁcities of the remaining KIRs are not as well characterized
thus far.
The inhibiting KIRs recognize the self HLA I as a ligand, and play
an important role in maintaining self tolerance by inhibiting NK
cells [11]. In other words, the cells that do not express self HLA I will
be destroyed by activated NK cells. Cancer can develop by over-
coming the host immune systems in a number of ways. One of the
mechanisms is decreasing the expression of HLA on cancer cells.
Through the decreased expression of HLA on the cell's surface,
delivery of the cancer antigen to T lymphocytes is decreased [12].
But the lack of expression of HLA on the cancer cells also may
decrease the inhibiting function of inhibiting KIR on NK cells.
There have been several reports concerning the relationship of
KIR genes and disease, including autoimmune disease, infectious
disease, transplantation, stem cell disease, and malignant diseases
[10,13]. In terms of the malignant diseases, there have been studies
of colon cancer, renal cancer, lung cancer, laryngeal cancer, malig-
nant melanoma, and cervical cancer [14e18]. However, two other
studies on colon cancer did not ﬁnd any differences in KIR genes
between the cancer group and the normal control group [15,16].
In the present study, we compared the HLA-Cw polymorphisms
and KIR genotypes between the colorectal cancer patients and
normal control group in Korean populations. We were trying to
investigate the characteristic of KIR genotypes and HLA-Cw poly-
morphisms in Korean colorectal cancer patients, and the bio-
immunological role of KIR genes in the development of the
colorectal cancer.
2. Materials and methods
2.1. Study group and control group
This study was performed using the peripheral blood of Korean
colorectal cancer patients and a normal control group from the
general Korean population. Of the colorectal cancer patients who
underwent surgery between March, 2007 and December 2008,
blood samples from 241 (60%, 241/399) patents’ were used for this
study. The control group was made up of 159 persons who were
healthy and had no disease and cancer history [19,20]. This study
was approved by the Institutional Review Board of the Catholic
Medical Center of The Catholic University of Korea (KC10TISI0382).
2.2. DNA extractions
Extractions of the DNA were performed using the AccuPrep
Genomic DNA Extraction kit (Bioneer corporation, Daejeon, Korea).In brief, the lymphocytes were separated from 1 ml of peripheral
blood using RBC lysis buffer (1 M TriseHCl. pH 7.6, 1 M KCl, 0.5 M
MgCl2, 0.5 M EDTA, 2.5% N-P40). The separated lymphocytes were
suspended with PBS 200 ml, and reacted with 20 ml of proteinase K
(20 mg/ml), and 200 ml of binding buffer (GC) for 10 min at 60 C,
and were then transferred to bind column with 100 ml of iso-
propanol. Washings were performed with washing buffer (W1,
W2). DNA was extracted through centrifugation with the washed
column and 200 ml of distilled water. The concentrations of
extracted DNA were checked using spectrophotometer, and used
for PCR at a concentration of 100 ng/ml.2.3. KIR genotyping
The KIR genes were determined by polymerase chain reaction
using sequence-speciﬁc primers (PCR-SSP) [14]. Inhibitory KIR
were typed for KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5,
KIR3DL1, KIR3DL2, and KIR3DL3, activating KIRs were typed for
KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1, and
pseudo KIRs were typed for KIR2DP1 and KIR3DP1 [21]. Speciﬁc
ampliﬁcations of the KIR genes were performed using 50 forward
and reverse primers. PCR was carried out with primers in a reaction
volume of 10 ml containing 1 buffer (50 mM KCl, 10 mM TriseHCl
pH 9.0, 1.5 mM MgCl2, 0.1% Triton X-100), 0.1e0.5 mM of each
nucleotide primer, 2.5 mM dNTPs, 100 ng genomic DNA and 0.25 U
I-start Taq Polymerase (iNtRON biotechnology, Seongnam, Korea).
The ampliﬁcations were carried out in a My Cycler™ thermocycler
(Bio-Rad, Hercules, CA, USA). A total of 35 cycles of PCR were
completed using the following steps: 25 s at 91 C, 45 s at 65 C, 30 s
at 72 C (ﬁrst 4 cycles); 25 s at 91 C, 45 s at 60 C, 30 s at 72 C (next
26 cycles); 25 s at 91 C, 60 s at 55 C, 120 s at 72 C (last 5 cycles)
and ﬁnally a 10-min extension at 72 C. The presence or absence of
PCR products was determined following separation on a 2% agarose
gel containing 0.5 mg/ml ethidium bromide.2.4. HLA-Cw allele genotyping
The genotyping of HLA-C was performed using the ampliﬁcation
refractory mutation system (ARMS)-polymerase chain reaction
(PCR) method. Each reaction contained a primer mixture consisting
of allele- or group-speciﬁc primer pairs as well as four internal
control primers matching nonallelic sequences (exon 5 of APC
gene). Speciﬁc ampliﬁcation of the HLA-C gene was performed
using 23 primers for HLA-C.
PCR was carried out in a reaction volume of 13 ml containing
100 ng genomic DNA, 0.8  buffer (40 mM KCl, 1.2 mM MgCl2,
8.0 mM TriseHCl pH 8.8, 0.08% Triton X-100), 5% dimethyl sulfoxide
(DMSO), 200 mMof each dNTP, 0.25 U Taq DNA polymerase (iNtRON
biotechnology, Seongnam, Korea), 1 mM of each sequence-speciﬁc
primer and 0.2 mM of internal control primers. The ampliﬁcations
were performed in a GeneAmp PCR system 9600 (PerkineElmer
Corporation). A total of 30 cycles were used for the ampliﬁcation
with the following steps: heating to 96 C for 1 min to denature the
DNA, denaturation at 96 C for 25 s, annealing at 70 C for 45 s and
extension at 72 C for 30 s (for the ﬁrst 5 cycles); 96 C for 25 s,
65 C for 45 s, 72 C for 30 s (for the next 21 cycles); 96 C for 25 s,
55 C for 60 s, 72 C for 120 s (for the last 4 cycles); and a ﬁnal 1 min
extension at 72 C. The presence or absence of PCR products was
determined following separation on a 1.5% agarose gel containing
0.5 mg/ml ethidium bromide.
HLA-C allele can be divided into HLA-C1 group that carries an
asparagines residue at position 80 (HLA-Cw01, 03, 07, 08, 09, 10, 12,
14) and HLA-C2 group that has a lysine residue at position 80 (HLA-
Cw02, 04, 05, 06, 15) [9].
Table 2
Frequencies of KIR genes of normal control group in the present study, compare to
those in the Western, and Japanese studies.
Function KIR gene Korean
N ¼ 159 (%)
UK11
N ¼ 255 (%)
Japan13
N ¼ 41 (%)
Inhibitory 2DL 1 100.0 96.9 100
2 12.6 46.7y 14.6
3 100.0 91.0þ 100
4 100.0 100 100
5 37.1 46.3 39.0
3DL 1 98.1 94.9 97.6
2 100.0 100 100
3 100.0 100 100
Activating 2DS 1 35.2 38.0 34.1
2 19.5 47.5k 14.6
3 18.2 25.1 14.6
4 98.1 94.9 97.6
5 20.8 30.6 24.4
3DS 1 35.2 38.0 29.3
Pseudo 2DP 1 100.0 96.9 NR
3DP 1 100.0 100 NR
NR ¼ not reported, y p-value ¼ 0.000, þ p-value ¼ 0.002, k p-value ¼ 0.000.
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When the values were greater than 5, chi-square tests were
applied to compare the frequencies of the KIR genes, and two-
tailed Fisher's exact tests were applied if the values were less
than 5. The relative risk was calculated using Woolf and Haldane's
methods, and considered signiﬁcant if the p-value was less than
0.05.
3. Results
3.1. Clinicopathologic ﬁndings on the colorectal cancer patients
A total of 241 colorectal cancer patients were enrolled. There
were 135 male patients (56%), and 106 female patients (44%). The
mean age was 61.7 ± 11.1 years old. The location of the tumor was
the colon in 138 patients (57.3%), and the rectum in 103 patients
(42.7%). The TNM stage was 0 in 4 patients, I in 36 patients, II in 71
patients, III in 99 and IV in 31 patients. There were 226 patients
with adenocarcinoma, 14 with mucinous adenocarcinoma. The
tumor differentiation was well-differentiated in 17 cases,
moderately-differentiated in 188 cases, poorly-differentiated in 18
cases, mucinous in 14 (Table 1).
3.2. Genetic polymorphisms of KIR genes among ethnic groups
KIR genotype of the control group of this study was compared to
the control group of the Western studies. In the Korean group, the
frequency of KIR2DL2 (12.6% vs. 46.7%, p < 0.0001) and KIR2DS2
(19.5% vs. 47.5%, p < 0.002) were lower, and KIR2DL3 (100% vs.
91.0%, p < 0.0001) was higher than in the Western group [15,16].
But the rates of the KIR genotype of this study's control group were
similar to the Japanese data [22], so therewere ethnic differences in
the KIR genotypes (Table 2).
3.3. Genetic polymorphisms of KIR genes of colorectal cancer
patients
KIR2DL1, KIR2DL4, KIR3DL2, KIR3DL3, KIR2DP1, and KIR3DP1
were always found, in both the control and the colorectal cancer
patients group. Average KIR genes per patient were 10.75 ± 2.0
(range, 9e15) in the normal control group, and 10.9 ± 2.0 (range,Table 1
Characteristics of the colorectal cancer patients.
Clinicopathological parameters N (%)
Gender
Male 135 (56%)
Female 106 (44%)
Tumor location
Colon 138 (57.3%)
Rectum 103 (42.7%)
Cell type
Adenocarcimona 226 (93.8%)
Mucinous carcinoma 14 (5.8%)
Differentiation
Well 17
Moderately 188
Poorly 18
Mucinous 14
TNM Stage
Tis 4 (1.7%)
I 36 (14.9%)
II 71 (29.5%)
III 99 (41.1%)
IV 31 (12.9)9e16) in the colorectal cancer patients group. The frequency of
KIR2DS5 (33.2% vs. 20.8%, p-value < 0.007, OR ¼ 1.9) was higher in
the colorectal cancer group than in the normal control group
(Table 3).
The colorectal cancer group was divided into a colon cancer
group and a rectal cancer group and compared to the control group.
In the colon cancer group, the frequency of KIR2DS5 (p-
value < 0.02, OR¼ 1.91) was higher than in the control group. In the
rectal cancer group, the frequency of KIR2DS5 (p-value < 0.03,
OR ¼ 1.88) was higher than in the control group, and the fre-
quencies of KIR3DL1 (p-value < 0.05, OR ¼ 0.26), KIR2DS2 (p-
value < 0.01, OR ¼ 0.35) and KIR2DS4 (p-value < 0.05, OR ¼ 0.26)
were signiﬁcantly lower than in the control group. Comparing the
colon and rectal cancer subgroups, the frequency of KIR2DS2 was
lower in the rectal cancer group than in the colon cancer group
(p < 0.05, Table 3).
By dividing colorectal cancer group according to the tumor
differentiation, it was found that there were no difference in the
frequencies of KIRs in the poorly-differentiated group, but the
frequency of KIR2DS5 (p-value < 0.02, OR ¼ 1.80) was higher in the
well or moderately-differentiated group (Table 4). In the rectal
cancer group, the frequency of KIR2DS3 (p-value < 0.03, OR ¼ 0.39)
was lower, and the frequency of KIR2DS5 (p-value < 0.03,
OR ¼ 1.97) was higher than in the control group (Table 4). Also, the
frequency of KIR2DS3 was lower in rectal cancer group than colon
cancer group (p < 0.03).3.4. Comparison of HLA-Cw allele between the colorectal cancer
patients and control group
The frequency of HLA-Cw6 (9.1% vs. 15.7%, p-value < 0.05,
OR¼ 0.54) and HLA-Cw7 (17.4% vs. 27.7%, p-value< 0.02, OR¼ 0.55)
were lower in the colorectal cancer group than in the normal
control group. There was no difference of the frequencies of HLA-
Cw in colon cancer group, but in the rectal cancer group, the fre-
quency of HLA-Cw7 (16.5% vs. 27.7%, p-value < 0.04, OR¼ 0.52) was
lower than in the control group (Table 5). There were differences
between the colon cancer and rectal cancer group in HLA-Cw14
allele (p-value < 0.03). However, there were no differences be-
tween the colorectal cancer group and normal control group when
HLA-Cws were classiﬁed into the HLA-C1 or HLA-C2 group. In
addition, there were no differences in the frequencies of HLA-C1/C2
homozygous or heterozygous.
Table 3
Frequencies of KIR genes in colon and rectal cancer patients.
Function KIR gene Colorectal cancer
N ¼ 241 (%)
Colon
N ¼ 138 (%)
Rectum
N ¼ 103 (%)
Normal control
N ¼ 159 (%)
Inhibitory 2DL 1 241 (100.0) 138 (100.0) 103 (100.0) 159 (100.0)
2 27 (11.2) 20 (14.5) 7 (6.8) 20 (12.6)
3 240 (99.6) 137 (99.3) 103 (100.0) 159 (100.0)
4 241 (100.0) 138 (100.0) 103 (100.0) 159 (100.0)
5 107 (44.4) 61 (44.2) 46 (44.7) 59 (37.1)
3DL 1 229 (95.0) 133 (96.4) 96 (93.2)k 156 (98.1)
2 241 (100.0) 138 (100.0) 103 (100.0) 159 (100.0)
3 241 (100.0) 138 (100.0) 103 (100.0) 159 (100.0)
Activating 2DS 1 106 (44.0) 58 (42.0) 48 (46.6) 56 (35.2)
2yy 31 (12.9) 23 (16.7) 8 (7.8)¶ 31 (19.5)
3 32 (13.3) 19 (13.8) 13 (12.6) 29 (18.2)
4 229 (95.0) 133 (96.4) 96 (93.2)** 156 (98.1)
5 80 (33.2)y 46 (33.3)þ 34 (33.0)þþ 33 (20.8)
3DS 1 99 (41.1) 53 (38.4) 46 (44.7) 56 (35.2)
Pseudo 2DP 1 241 (100.0) 138 (100.0) 103 (100.0) 159 (100.0)
3DP 1 241 (100.0) 138 (100.0) 103 (100.0) 159 (100.0)
y p-value < 0.007, Odd ratio (OR) ¼ 1.9, þ p-value < 0.02, OR ¼ 1.91, k p-value < 0.05, OR ¼ 0.26.
¶ p-value < 0.01, OR ¼ 0.35, ** p-value < 0.05, OR ¼ 0.26, þþ p-value < 0.03, OR ¼ 1.88.
yyp-value<0.05 (colon vs. rectum).
Table 4
Frequencies of KIR genes in colon and rectal cancer patients according to the tumor differentiation.
Function KIR gene Well or moderately differentiated Poorly differentiated Normal
Colorectal cancer Colon Rectum Colorectal cancer Colon Rectum
N ¼ 203 (%) N ¼ 115 (%) N ¼ 88 (%) N ¼ 18 (%) N ¼ 14 (%) N ¼ 4 (%) N ¼ 159 (%)
Inhibitory 2DL 1 203 (100.0) 115 (100.0) 88 (100.0) 18 (100.0) 14 (100.0) 4 (100.0) 159 (100.0)
2 22 (10.8) 12 (10.4) 10 (11.4) 3 (16.7) 2 (14.3) 1 (25.0) 20 (12.6)
3 202 (99.5) 114 (99.1) 88 (100.0) 18 (100.0) 14 (100.0) 4 (100.0) 159 (100.0)
4 203 (100.0) 115 (100.0) 88 (100.0) 18 (100.0) 14 (100.0) 4 (100.0) 159 (100.0)
5 90 (44.3) 54 (47.0) 36 (40.9) 5 (27.8) 4 (28.6) 1 (25.0) 59 (37.1)
3DL 1 193 (95.1) 110 (95.7) 83 (94.3) 17 (94.4) 14 (100.0) 3 (75.0) 156 (98.1)
2 203 (100.0) 115 (100.0) 88 (100.0) 18 (100.0) 14 (100.0) 4 (100.0) 159 (100.0)
3 203 (100.0) 115 (100.0) 88 (100.0) 18 (100.0) 14 (100.0) 4 (100.0) 159 (100.0)
Activating 2DS 1 89 (43.8) 52 (45.2) 37 (42.0) 5 (27.8) 4 (28.6) 1 (25.0) 56 (35.2)
2 25 (12.3) 14 (12.2) 11 (12.5) 3 (16.7) 2 (14.3) 1 (25.0) 31 (19.5)
3 29 (14.3) 22 (19.1)¶ 7 (8.0)þ 1 (5.6) 1 (7.1) 0 (0.0) 29 (18.2)
4 193 (95.1) 110 (95.7) 83 (94.3) 17 (94.4) 14 (100.0) 3 (75.0) 156 (98.1)
5 65 (32.0)y 35 (30.4) 30 (34.1)k 4 (22.2) 3 (21.4) 1 (25.0) 33 (20.8)
3DS 1 84 (41.4) 50 (43.5) 34 (38.6) 5 (27.8) 4 (28.6) 1 (25.0) 56 (35.2)
Pseudo 2DP 1 203 (100.0) 115 (100.0) 88 (100.0) 18 (100.0) 14 (100.0) 4 (100.0) 159 (100.0)
3DP 1 203 (100.0) 115 (100.0) 88 (100.0) 18 (100.0) 14 (100.0) 4 (100.0) 159 (100.0)
y P < 0.02, OR ¼ 1.80; þ P < 0.03, OR ¼ 0.39; k P < 0.03, OR ¼ 1.97.
¶ P < 0.03 (colon vs. rectum).
Table 5
Frequencies of HLA-Cw type in colorectal cancer patients.
Colorectal cancer Colon Rectum Normal control
N ¼ 241 (%) N ¼ 138 (%) N ¼ 103 (%) N ¼ 159 (%)
HLA-C1 group
HLA-Cw1 80 (33.2) 47 (34.1) 33 (32.0) 59 (37.1)
HLA-Cw7 42 (17.4)þ 25 (18.1) 17 (16.5)k 44 (27.7)
HLA-Cw8 53 (22.0) 33 (23.9) 20 (19.4) 29 (18.2)
HLA-Cw9 52 (21.6) 31 (22.5) 21 (20.4) 23 (14.5)
HLA-Cw10 69 (28.6) 37 (26.8) 31 (30.1) 39 (24.5)
HLA-Cw12 10 (4.1) 5 (3.6) 5 (4.9) 11 (6.9)
HLA-Cw14¶ 58 (24.1) 26 (18.8) 32 (31.1) 34 (21.4)
HLA-C2 group
HLA-Cw2 1 (0.4) 0 (0.0) 1 (1.0) 0 (0.0)
HLA-Cw4 32 (13.3) 21 (15.2) 11 (10.7) 21 (13.2)
HLA-Cw5 9 (3.7) 6 (4.3) 3 (2.9) 6 (3.8)
HLA-Cw6 22 (9.1)y 12 (8.7) 10 (9.7) 25 (15.7)
HLA-Cw15 19 (7.9) 11 (8.0) 8 (7.8) 8 (5.0)
HLA-C1C1 161 (66.8) 90 (65.2) 71 (68.9) 105 (66.0)
HLA-C1C2 74 (30.7) 46 (33.3) 28 (27.2) 48 (30.2)
HLA-C2C2 6 (2.5) 2 (1.4) 4 (3.9) 6 (3.8)
y p-value < 0.05, OR ¼ 0.54,þ p-value < 0.02, OR¼ 0.55, k p-value < 0.04, OR¼ 0.52.
¶ p-value < 0.03 (colon vs. rectum).
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The frequency of KIR2DS2 with HLA-C1 homozygous was lower
in the colorectal cancer group than in the normal control group
(5.8% vs. 14.5%, p-value < 0.004, OR ¼ 0.36, Table 6). There were no
differences in the frequencies of the KIR gene in colon cancer group,
but in rectal cancer group, the frequency of KIR2DS2 with HLA-C1
was decreased signiﬁcantly (2.9% vs. 14.5%, p-value < 0.004,
OR ¼ 0.18, Table 6).
4. Discussion
NK cells that express CD56 in the absence of CD3 provide front-
line defense against viral infections and cancer cells without pre-
vious sensitization [3,4].
There are many receptors on the surface of human NK cells. Of
these, KIR, which recognizes HLA class I as their ligands, can acti-
vate or inhibit NK cells plays an important role in controlling the
function of NK cells [5].
It is known that there are ethnic differences in the KIR genotype.
In the present study, we compare the frequencies of KIR gene of the
Table 6
The association of KIR genes and their ligands between colorectal cancer patients and control.
Colorectal cancer Colon Rectum Normal control
N ¼ 241 (%) N ¼ 138 (%) N ¼ 103 (%) N ¼ 159 (%)
KIR2DL1 with HLA-C2 80 (33.2) 48 (34.8) 32 (31.1) 54 (34.0)
with HLA-C2C2 6 (2.5) 2 (1.4) 4 (3.9) 6 (3.8)
KIR2DL2 with HLA-C1 26 (10.8) 20 (14.5) 6 (5.8) 19 (12.0)
with HLA-C1C1 12 (5.0) 10 (7.2) 2 (1.9) 12 (7.5)
KIR2DL3 with HLA-C1 234 (97.1) 135 (97.8) 99 (96.1) 153 (96.2)
with HLA-C1C1 161 (66.8) 90 (65.2) 71 (68.9) 105 (66.0)
KIR2DS1 with HLA-C2 34 (14.1) 24 (17.4) 10 (9.7) 22 (13.8)
With HLA-C2C2 1 (0.4) 1 (0.7) 0 (0.0) 3 (1.9)
KIR2DS2 with HLA-C1 30 (12.4) 23 (16.7) 7 (6.8)þ 30 (18.9)
With HLA-C1C1 14 (5.8)y 11 (8.0) 3 (2.9)k 23 (14.5)
y p-value < 0.004, OR ¼ 0.36, þ p-value < 0.007, OR ¼ 0.31, k p-value < 0.004, OR ¼ 0.18.
What is already known on this topic?
KIR2DS5 is higher in Korean colorectal cancer patients. And
KIR2DS2 in presence of its ligand may have a protective
effect against colorectal cancer.
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studies [15,16]. In the Korean populations, the frequencies of
KIR2DL2 and KIR2DS2 were lower than in the Western groups, and
the frequency of KIR2DS3was higher. But therewas no difference in
the frequency of KIR genes between the Korean and Japanese
control groups [22]. So we could conﬁrm the presence of ethnic
differences in KIR genes (Table 2).
In the present study, we tested eight inhibiting KIR genes (2DL1,
2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, 3DL3), six activating KIR genes
(2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1), and two pseudo-genes
(2DP1, 3DP2). We found that the frequency of the KIR2DS5 gene
was higher in colorectal cancer group, this difference was observed
in the well or moderately-differentiated tumor subgroup. In the
rectal cancer subgroup, the frequency of KIR2DS5 was higher, and
the frequencies of KIR3DL1, KIR2DS2, and KIR2DS4were lower than
normal control group. For this reason, there may be some different
immune mechanisms in cancer developments between colon and
rectal cancer.
Similar to our study's results, Paladino et al. reported that the
frequency of KIR2DS5 was higher, and the frequencies of KIR2DL2
and KIR2DS2 were lower in hepatitis C patients [23]. But Nowak
et al. reported that the frequency of KIR2DS5was lower when there
was ankylosing spondylitis, endometriosis, and renal transplant
rejection [24]. So we can deduce that KIR2DS5 may play a different
role in different diseases.
KIRs bind to speciﬁc HLA-C as their ligand. KIR2DL1 and
KIR2DS1 are known to bind to HLA-C2, and KIR2DL3, KIR2DS2, and
KIR2DL2 are known to bind to HLA-C1 [10]. But there are differ-
ences in the inhibiting effect among KIRs. KIR2DL1/HLA-C2 binding
is the most powerful, followed by KIR2DL2/HLA-C1, KIR2DL3/HLA-
C1 [10].
In the present study, we compared the frequency of KIR ac-
cording to KIR genotype and its ligand HLA-Cw combination.
The frequency of KIR2DS2 was lower in the HLA-C1 homozygous
group (5.8% vs 14.5%, p-value < 0.004, OR ¼ 0.36), and in the
rectal cancer subgroup, the frequency of the KIR2DS2/HLA-C1
combination was lower (Table 6). Similarly to our ﬁndings,
Middleton et al. reported that KIR2DS2 or KIR2DL2 was lower
with HLA-C1 group in leukemic patients [25]. They also
concluded that the HLA-C1/KIR2DS2 combination can reduce the
risk of leukemia. Accordingly, we can deduce that the HLA-C1
and KIR2DS2 combination can activate NK cells and plays
some role in protecting against the development of colorectal
cancer.
In the present study, the frequencies of HLA-Cw6 and HLA-Cw7
were lower in colorectal cancer group than in the normal control
group. But after classiﬁcation into an HLA-C1 and an HLA-C2 group,
there was no difference between the colorectal cancer and normal
control group.There are several shortcomings to our study. The ﬁrst is the
limitation of the genetic study; speciﬁcally, we cannot know
how exactly KIR genes are expressed on the cell surface. For this
reason, further studies are needed to investigate the expression
of KIR on NK cells. The other drawback is the possibility of other
ligands to KIRs. Currently, not all of the ligands to KIRs are
elucidated. Katz et al. reported that in malignant melanoma
patients, there is another ligand to KIR2DS4 other than HLA [26].
In the present study, the frequency of KIR2DS5 was higher in
colorectal cancer patients. However its ligand is not known yet,
therefore further studies are needed to ﬁnd the ligand of
KIR2DS5.
In conclusion, the frequency of KIR2DS5 is higher in Korean
colorectal cancer patients, and in the rectal cancer subgroup, the
frequencies of KIR3DL1, KIR2DS2 and KIR2DS4 are lower, there may
be some immunologic differences between colon and rectal can-
cers. And among the patients with HLA-C1 homozygote, the fre-
quency of KIR2DS2 is decreased. Therefore, KIR2DS2 in presence of
its ligand (HLA-C1 group) may have a protective effect against
colorectal cancer.Ethical approval
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